Effect of mycelial extract of Clavicorona pyxidata on acetylcholinesterase and β-secretase activity in vitro

Journal of Microbiology

Volumn 44, Issue 5, 2006, Pages 502-507

  Lee, Tae Hee ^a   Park, Young Il ^b   Han, Yeong Hwan ^a  

^a Dongguk University   (South Korea)

^b Dongguk University   (South Korea)

Author keywords

secretase; Acetylcholinesterase; Alzheimer's disease; Clavicorona pyxidata

Indexed keywords

ARTOMYCES PYXIDATUS; RATTUS;

ACETYLCHOLINESTERASE; ALCOHOL; BUTANOL; CHOLINESTERASE INHIBITOR; SECRETASE;

ANIMAL; ARTICLE; BASIDIOMYCETES; CELL STRAIN; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; METABOLISM; MYCELIUM; RAT;

ACETYLCHOLINESTERASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BASIDIOMYCOTA; BUTANOLS; CELL SURVIVAL; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ETHANOL; MYCELIUM; PC12 CELLS; RATS;

EID: 33947183127     PISSN: 12258873     EISSN: 12258873     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Cai, H., Y. Wang, D. McCarthy, H. Wen, D.R. Borchelt, D.L. Price, and P.C. Wong. 2001. Nature Neuroscience 4, 233-234.
2. Chemnitius, J.M., K.H. Haselmeye, B.D. Gonska, H. Kreuzer, and R. Zech. 1996. Indirect parasympathomimetic activity of metochlopramide: Reversible inhibition of cholinesterase from human central nervous system and blood. Pharmacol. Res. 34, 65-72.
3. Citron, M. 2004. β-Secretase inhibition for the treatment of Alzheimer's disease-promise and challenge. Trends Pharmacol. Sci. 25, 92-97.
4. Corner, J.H. 1970. A monograph of Clavaria and allied Genera. Beih. Nova Hedwigia 33, 1-299.
5. Coyle, J.T., D.L. Price, and M.R. Delong. 1983. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 219, 1184-1190.
6. Ellman, G.L., K.D. Courtney, Jr., V. Andres, and R.M. Featherstone. 1961. A new and rapid colorimetric determination of acetylcholineesterase activity. Biochem. Pharmacol. 7, 88-95.
7. Enz, A., R. Amstutz, H. Boddeke, G. Gmelin, and J. Malanowski. 1993. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease. Prog. Brain Res. 98, 431-438.
8. Ghosh, A.K., D. Shin, D. Downs, G. Koelsch, X. Lin, J. Ermolieff, and J. Tang. 2000. Design of potent inhibitors for human brain memapsin 2 (β-secretase). J. Am. Chem. Soc. 122, 3522-3523.
9. Ghosh, A.K., L. Hong, and J. Tang. 2002. β-secretase as a therapeutic target for inhibitor drugs. Curr. Med. Chem. 9, 1135-1144.
10. Lee, H.J., J.S. Kim, G.Y. Heo, K.B. Lee, I.K. Rhee, and K.S. Song. 1999. Inhibitory activities of basidiomycetes on prolyl endopeptidase, acetylcholinesterase, and coagulation. J. Kor. Agr. Chem. Soc. 42, 336-343.
11. Lee, T.H. 2004. Ph. D. thesis. Dongguk University, Seoul, Korea.
12. Lee, T.H., J.M. Kim, and Y.H. Han. 2006. Optimized culture condition and enzyme activity of the mycelia of Clavicorona pyxidata. Kor. J. Microbiol. 41, 98-102.
13. Leung, D., G. Abbenante, and D.P. Fairlie. 2000. Protease inhibitors: current status and future prospects. J. Med. Chem. 43, 305-341.
14. Li, R., R.K. Lindholm, L.B. Yang, X. Yue, M. Citron, R. Yan, T. Beach, L. Sue, M. Sabbagh, H. Cai, P. Wong, D. Price, and Y. Shen. 2004. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc. Nat. Acad. Sci. USA 101, 3632-3637.
15. Luo, Y., B. Bolon, S. Kahn, B.D. Bennett, S. Babu-Khan, P. Denis, W. Fan, H. Kha, J. Zhang, Y. Gong, L. Martin, J.C. Louis, Q. Yan, W.G. Richards, M. Citron, and R. Vassar. 2001. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nature Neuroscience 4, 231-232.
16. McGeer, P.L. and E.G. McGeer. 1995. Alzheimer's disease: Arthritis of the brain? Drug News Prospect 8, 80-83.
17. Miller, O.K. 1977. Mushrooms of North America, p. 158-162. In E.P. Dutton (ed.), Academic Press, New York, USA
18. Page, M., N. Bejaoui, B. Cliq-Mars, and P. Lemieux. 1988. Optimization of the tetrazolium-based colorimetric assay for the measurement of cell number and cytotoxicity. Int. J. Immunol. 10, 85-793.
19. Parihar, M.S. and T. Hemnani. 2004. Alzheimer's disease pathogenesis and therapeutic interventions. J. Clin. Neurosci. 11, 456-467.
20. Plattner, J.J. and D.W. Norbeck. 1990. Drug Discovery Technologies, p. 92-126. In C.R. Clark and W.H. Moos (ed.), Ellis Horwood Limited, Chichester, West Sussex
21. Plumb, J.A., R. Milroy, and S.B. Kaye. 1989. Effect of the pH dependence of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide-formazon absorption on chemosensitivity determined by novel tetrazolium-based assay. Cancer Res. 49, 4435-4440.
22. Sinha, S., J.P. Anderson, R. Barbour, G.S. Basi, R. Caccavello, D. Davis, M. Doan, H.F. Dovey, N. Frigon, J. Hong, K. Jacobson-Croak, N. Jewett, P. Keim, J. Knops, I. Lieberburg, M. Power, H. Tan, G. Tatsuno, J. Tung, D. Schenk, and et al. 1999. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402, 537.
23. Wolfe, M.S. 2001. Secretase targets for Alzheimer's disease: identification and therapeutic potential. J. Med. Chem. 44, 2039-2060.